Abstract
A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).
| Original language | English |
|---|---|
| Pages (from-to) | 163-168 |
| Number of pages | 6 |
| Journal | Cerebrovascular Diseases |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- Cerebral ischemia
- Excitatory amino acids
- GM1 ganglioside therapy
- Monosialoganglioside
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Clinical Neurology
- Neurology
Cite this
GM1 ganglioside therapy in acute ischemic stroke. / Angeleri, F.; Scarpino, O.; Martinazzo, C.; Mauro, A.; Magi, M.; Pelliccioni, G.; Rapex, G.; Bruno, Roberto.
In: Cerebrovascular Diseases, Vol. 2, No. 3, 1992, p. 163-168.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - GM1 ganglioside therapy in acute ischemic stroke
AU - Angeleri, F.
AU - Scarpino, O.
AU - Martinazzo, C.
AU - Mauro, A.
AU - Magi, M.
AU - Pelliccioni, G.
AU - Rapex, G.
AU - Bruno, Roberto
PY - 1992
Y1 - 1992
N2 - A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).
AB - A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).
KW - Cerebral ischemia
KW - Excitatory amino acids
KW - GM1 ganglioside therapy
KW - Monosialoganglioside
UR - http://www.scopus.com/inward/record.url?scp=20244389101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20244389101&partnerID=8YFLogxK
U2 - 10.1159/000109009
DO - 10.1159/000109009
M3 - Article
AN - SCOPUS:20244389101
VL - 2
SP - 163
EP - 168
JO - Cerebrovascular Diseases
JF - Cerebrovascular Diseases
SN - 1015-9770
IS - 3
ER -